News and Press Releases
Neurotech Announces Mente Partnership with the Australian Neurofeedback Institute
New qEEG service enhances support for clinics using or recommending Mente in Australia
Malta and Perth, Australia – Neurotech International Limited (ASX: NTI) are pleased to announce a new partnership between Mente and the Australian Neurofeedback Institute (“ANFI”) which will bring together the advanced neuroscience skills of ANFI along with Mente’s clinically proven therapy for the Australian Market. ANFI as the centre of excellence collaborates with the research partners in academia, world leaders in mental health treatment and neuromodulation technology manufacturers to develop, deliver, expand and promote cutting edge treatments, client outcomes and industry training.
Under the first phase of the partnership, the team at ANFI will be providing qEEG services and expert analysis to support clinicians working with Mente. ANFI’s services and contact details are available at https://anfi.org.au/.
Clinically proven Mente helps ASD children to learn to engage positively with their environment and self-regulate attention and mood. Mente is available through https://www.mentetech.com/.
Neurotech CEO and Managing Director, Peter Griffiths, said: “We are delighted to be working alongside the experts at ANFI to support Australian clinics in offering qEEGs to customers. We believe our Mente users and the wider community will greatly benefit from ANFI’s clinical knowledge, analysis services, training, mentorship and research opportunities.”
ANFI Deputy Director, Sejla Murdoch, said: “We are excited to be working in collaboration with the Mente team. Mente’s cutting-edge approach enables neurofeedback therapy to be provided both in clinic and at home under a supervised clinical programme. We are looking forward to supporting clinics in improving outcomes for their clients. ANFI will provide the expert EEG Assessment to support the Mente treatment for children who come to our service.”